In This Article:
Lannion, 28 April 2025 - 5.45pm
REVENUE GROWTH OF+ 12.4% IN THE 1st QUARTER
The Lumibird Group (FR0000038242 - LBIRD), European leader in laser technologies, recorded consolidated revenue growth of+ 12.4% (+ 11.7% at constant exchange rates and scope) to €49.4m in the 1st quarter of 2025.
Consolidated revenues (unaudited)
| Sales (€M) | 2025 | 2024 | Reported change | On a like-for-like basis |
| 1st quarter | 49.4 | 43.9 | +12.4% | +11.7% |
| of which |
|
|
|
|
| Photonics | 23.9 | 20.6 | +15.8% | +15.1% |
| Medical | 25.5 | 23.3 | +9.4% | +8.6% |
Lumibird's consolidated revenues came to €49.4m at 31 March 2025, an increase of+ 12.4% on a reported basis and+ 11.7% at constant exchange rates, with no perimeter effect.
By division
Photonics division grew by+ 15.8% to €23.9m (+15.1% at constant exchange rates), still driven by the Defence/Space business, whose sales rose by+ 37.8% to €10.5m (+ 37.1% at constant exchange rates) as a result of the roll-out of multi-year contracts and the delivery of the order book.
Industrial and Scientific sales rose by+ 7.0% to €5.9m (up+ 6.2% at constant exchange rates). This figure includes sales of €0.5m from the Continuum range, acquired last October. Production of the Continuum range was transferred to Lumibird at the end of February 2025.
Medtech sales fell slightly by 2.3% to €3.9m (-3.2% at constant exchange rates), impacted by the phasing of deliveries over the year 2025.
ETS (Environment, Topography and Security) sales rose by 2.4% to €3.6m (up 1.8% at constant exchange rates), with a recovery in systems sales following the commercial reorganisation of 2024.
The Medical division grew by+ 9.4% to €25.5m (+8.6% at constant exchange rates). This growth was driven by diagnostics and buoyant dry eye sales. The breakdown of sales in Q1 was 23% for diagnostic equipment and 77% for treatment products.
By geographical area
The breakdown of revenues by geographical area is as follows:
| Q1 revenues (€m) | Photonics | Chge | Medical | Chge |
| EMEA | 13.8 | +16.2% | 7.6 | -6.0% |
| Americas | 4.5 | +54.1% | 6.6 | +2.1% |
| Asia-Pacific | 2.9 | -17.5% | 8.1 | +29.1% |
| Rest of the world | 2.7 | +16.9% | 3.1 | +28.9% |
| Total | 23.9 | +15.8% | 25.5 | +9.4% |
Unaudited data
The Photonics Division's strong growth in Europe was driven by the momentum of the Defence/Space business. Growth in the Americas was driven in particular by the integration of the Continuum range of lasers. Sales in the Asia-Pacific region were down, impacted by uncertainty over the impact of tariffs on products manufactured in the USA.
The Medical division's growth is mainly due to dynamic direct sales via its subsidiaries (USA, Japan, Poland, Scandinavia). The mixed performance in EMEA and the Americas was due to a more pronounced seasonal effect on regional distributors in the first quarter of 2025.